- ISIN
- US87650L1035
- CUSIP
- 87650L103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 16, 2020
Highlights
- Market Cap
- $2.73B
- Enterprise Value
- $2.63B
- EPS (TTM)
- -$1.13
- Total Revenue (TTM)
- $535.08M
- Gross Profit (TTM)
- $483.93M
- EBITDA (TTM)
- -$39.55M
- Year Range
- $38.51 - $85.25
- Target Price
- $89.33
- ROA (TTM)
- -8.31%
- ROE (TTM)
- -13.83%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TARS Performance Chart
Tarsus Pharmaceuticals, Inc. (TARS) is down 22.4% since the beginning of the year. At $64 per share, TARS is trading 25.4% below its 52-week high of $85. Investors who bought $1,000 worth of TARS shares 5 years ago would now be looking at an investment worth $2,097.
Loading charts...
Returns By Period
Tarsus Pharmaceuticals, Inc. (TARS) has returned -22.37% so far this year and 56.36% over the past 12 months.
Tarsus Pharmaceuticals, Inc.
- 1D
- 0.63%
- 1M
- 2.09%
- YTD
- -22.37%
- 6M
- -22.47%
- 1Y
- 56.36%
- 3Y*
- 51.58%
- 5Y*
- 15.96%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
TARS Monthly Returns History
Based on dividend-adjusted daily data since Oct 16, 2020, TARS's average daily return is +0.18%, while the average monthly return is +3.50%. At this rate, an investment would double in approximately 1.7 years.
Historically, 54% of months were positive and 46% were negative. The best month was Dec 2020 with a return of +71.0%, while the worst month was May 2022 at -24.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, TARS closed higher 49% of trading days. The best single day was Oct 16, 2020 with a return of +27.0%, while the worst single day was Jul 25, 2023 at -24.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.18% | 17.01% | -7.11% | -9.32% | -6.62% | 7.00% | -22.37% | ||||||
| 2025 | -2.91% | -17.26% | 15.49% | 1.05% | -17.26% | -5.68% | -4.17% | 50.90% | 1.45% | 15.78% | 16.20% | 2.40% | 47.88% |
| 2024 | 34.52% | 40.31% | -4.89% | -13.54% | 4.87% | -17.54% | -10.63% | 11.61% | 21.32% | 35.27% | 17.89% | 5.57% | 173.43% |
| 2023 | 7.50% | -1.71% | -18.85% | 18.70% | 12.27% | 7.88% | 21.80% | -20.45% | 1.48% | -19.86% | 16.08% | 22.50% | 38.13% |
| 2022 | -10.80% | -12.16% | -4.59% | 8.86% | -24.90% | 6.18% | 2.88% | 2.40% | 11.31% | 7.59% | -8.74% | -12.79% | -34.84% |
| 2021 | -8.78% | -3.85% | -11.09% | -4.69% | 8.46% | -13.03% | -22.12% | 17.41% | -18.68% | 28.82% | -4.18% | -15.41% | -45.56% |
Benchmark Metrics
Tarsus Pharmaceuticals, Inc. has an annualized alpha of 37.46%, beta of 0.88, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 16, 2020.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (97.76%) than losses (38.42%) - typical of diversified or defensive assets.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 37.46%
- Beta
- 0.88
- R²
- 0.05
- Upside Capture
- 97.76%
- Downside Capture
- 38.42%
Return for Risk
Risk / Return Rank
TARS ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Tarsus Pharmaceuticals, Inc. (TARS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TARS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.73 | ||
| Sortino ratioReturn per unit of downside risk | -0.62 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.37 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | 1.86 | 2.78 | -0.92 |
| Martin ratioReturn relative to average drawdown | 4.02 | 12.44 | -8.42 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Tarsus Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Tarsus Pharmaceuticals, Inc. was 77.67%, occurring on May 6, 2022. Recovery took 643 trading sessions.
The current Tarsus Pharmaceuticals, Inc. drawdown is 22.97%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -77.67%May 2022 | 1y 4mo | 2y 6mo | 3y 11moDec 2020 - Nov 2024 |
2025 bear market2025 | -31.82%Jul 2025 | 5mo 25d | 22d | 6mo 17dFeb 2025 - Aug 2025 |
2026 bear market2026 | -30.42%Jun 2026 | 5mo 8d | — | 5mo 29dDec 2025 - now |
2020 bear market2020 | -26.19%Nov 2020 | 19d | 12d | 1mo 1dNov 2020 - Dec 2020 |
2020 bear market2020 | -21.76%Oct 2020 | 7d | 6d | 13dOct 2020 - Nov 2020 |
Drawdown Indicators
| TARS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.67% | -56.78% | -20.89% |
Max Drawdown (1Y)Largest decline over 1 year | -30.42% | -9.10% | -21.32% |
Max Drawdown (3Y)Largest decline over 3 years | -47.28% | -18.90% | -28.38% |
Max Drawdown (5Y)Largest decline over 5 years | -63.09% | -25.43% | -37.66% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -22.97% | -1.80% | -21.17% |
Average DrawdownAverage peak-to-trough decline | -40.46% | -10.71% | -29.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.06% | 2.03% | +12.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Tarsus Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Tarsus Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TARS relative to other companies in the Biotechnology industry. Currently, TARS has a P/S ratio of 5.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TARS in comparison with other companies in the Biotechnology industry. Currently, TARS has a P/B value of 7.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TARS
Add Tarsus Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TARS